AlloCure, Inc. is a pioneer in the development of cell therapies for the treatment of kidney disease and is a leader in the acute kidney injury field. The company's proprietary technology enables the isolation and expansion of mesenchymal stem cells (MSC), obtained via conventional bone marrow donation, which can then be administered off-the-shelf to any patient in need without requiring tissue matching or immunosuppressants. The company's most advanced program, AC607, targeting acute kidney injury, is entering phase 2 clinical development and represents the first cell therapy to treat this life threatening condition.